Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/1/18 (What's New)

Summary

  • Based on available data, the combination of a lopinavir/ritonavir plus either NRTIs or twice-daily raltegravir can be used to successfully treat patients experiencing virologic failure of first-line NNRTI-based therapy
    • However, in clinical practice in the developed world it is more common for boosted darunavir or dolutegravir plus NRTIs to be used in this setting
    • Results from the DAWNING trial seem to support the efficacy of dolutegravir plus 2 NRTIs after failure of a first-line regimen consisting of an NNRTI plus 2 NRTIs, with the caveat that in this study the second-line regimen was required to include at least 1 active NRTI by resistance testing

Action required

Keywords: Management of Treatment-Experienced Patients, Resistance Testing

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.